Literature DB >> 20291

Effect of dose on the pharmacokinetics of intravenous nicotine in the rat.

R P Miller, K S Rotenberg, J Adir.   

Abstract

The pharmacokinetics of [methyl-14C]nicotine were evaluated in male Fischer-344 rats following the iv injection of 0.08-, 0.4-, or 0.8-mg/kg doses. Independent of dose, the concentration of nicotine declined biexponentially with a mean half-life ranging from 0.92 to 1.10 hr. However, the total plasma clearance of nicotine increased (p less than 0.05) from a mean value of 2.53 liter/hr-kg at the 0.08 mg/kg dose to mean values of 3.88 and 4.04 at the 0.4- and 0.8-mg/kg doses, respectively. There were no dose-related differences in the half-life of formation of the major metabolite, cotinine (range 0.33-0.46 hr) or the half-life of its elimination (range 5.39-6.63 hr). However, the areas under the cotinine plasma concentration-time curves did not increase proportionately with the dose of nicotine, indicating that the dose-related increase in the total plasma clearance of nicotine is not due to an increase in its biotransformation to cotinine. Similar conclusions were obtained with regard to the disposition kinetics of other polar metabolites of nicotine. The urinary excretions of nicotine and its metabolites were dose-independent.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 20291

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations.

Authors:  Mark G LeSage; Daniel E Keyler; Greg Collins; Paul R Pentel
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

2.  Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat.

Authors:  Sabina H L de Villiers; Nina Lindblom; Genadiy Kalayanov; Sandra Gordon; Anette M Johansson; Torgny H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-16       Impact factor: 3.000

3.  Effect of menthol on nicotine pharmacokinetics in rats after cigarette smoke inhalation.

Authors:  Cyril V Abobo; Jing Ma; Dong Liang
Journal:  Nicotine Tob Res       Date:  2012-02-06       Impact factor: 4.244

Review 4.  Cellular events in nicotine addiction.

Authors:  Rachel E Penton; Robin A J Lester
Journal:  Semin Cell Dev Biol       Date:  2009-01-20       Impact factor: 7.727

5.  Nicotine modulates alcohol-seeking and relapse by alcohol-preferring (P) rats in a time-dependent manner.

Authors:  Sheketha R Hauser; Bruk Getachew; Scott M Oster; Ronnie Dhaher; Zheng-Ming Ding; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Alcohol Clin Exp Res       Date:  2011-06-20       Impact factor: 3.455

6.  Ibogaine and the dopaminergic response to nicotine.

Authors:  I M Maisonneuve; G L Mann; C R Deibel; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

Review 7.  Consideration of species differences in developing novel molecules as cognition enhancers.

Authors:  Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson
Journal:  Neurosci Biobehav Rev       Date:  2012-10-12       Impact factor: 8.989

Review 8.  Clinical pharmacokinetics of nicotine.

Authors:  C K Svensson
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

9.  Chronic nicotine exposure induces a long-lasting and pathway-specific facilitation of LTP in the amygdala.

Authors:  Yan-You Huang; Eric R Kandel; Amir Levine
Journal:  Learn Mem       Date:  2008-08-06       Impact factor: 2.460

10.  Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats.

Authors:  Matthew R Costello; Daisy D Reynaga; Celina Y Mojica; Nurulain T Zaveri; James D Belluzzi; Frances M Leslie
Journal:  Neuropsychopharmacology       Date:  2014-02-11       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.